| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Biosensor Latest Results
|
|
|
investor
Senior |
20-Nov-2006 11:03
|
|
x 0
x 0 Alert Admin |
The mgmt of Bisosenors have not given a difinite date on CE mark approval, but they have said that it is aquestion of 'when' and not 'if'. The mkt is probably worried about them not getting the CE mark - hence the recent price weakness. Citigroup has just come out with a report talking abt J & J's takeover of Conors, and they say that it is possible that Biosensor may be played up because of this. Whatever it is, it is best to be careful on this stk - quite speculative at the moment. |
| Useful To Me Not Useful To Me | |
|
junjun
Member |
20-Nov-2006 09:27
|
|
x 0
x 0 Alert Admin |
It seems that CE approval has been submitted for quite some time already and source said that by end 2006. Anyone know when will the likely date? Only 6 more weeks to the end of 2006. Should be pretty soon right? |
| Useful To Me Not Useful To Me | |
|
|
|
|
investor
Senior |
17-Nov-2006 21:14
|
|
x 0
x 0 Alert Admin |
In the case of Conors - it has a unique stent technology, where the drug and polymer is stored on small indentations (called 'reservoirs') on the stent surface, whereby, the stent is able to deliver multiple drugs, as well as control the direction of delivery of the drug, plus its current drug eluting stent (DES) has a biodegradable polymer, which makes it attractive to J & J. Whether Biosensors will be attractive as a takeover target depends on its current technology. It has a proprietary drug and biodegradable polymer, which seems to be as good as the current commercial products, albeit with biodegradable polymer (it is the in-thing to be biodegradable), but a lot of companies out there are also racing ahead with new technologies, like biodegradable stents !, etc. I would say that Biosensors is probably ahead of most of the competition in the biodegradable area, but unfortunately, they have yet to receive the CE Mark approval to start marketing their product, in Europe - the place where most companies will start first. (in mkting the product, that is). |
| Useful To Me Not Useful To Me | |
|
junjun
Member |
17-Nov-2006 17:40
|
|
x 0
x 0 Alert Admin |
Does that means Biosensors has the potential for being bought over by bigger company? |
| Useful To Me Not Useful To Me | |
|
investor
Senior |
17-Nov-2006 16:56
|
|
x 0
x 0 Alert Admin |
Johnson & Johnson is buying over Conors Medsystem in the States for US$1.4 billion. Conors has a similar product to Biosensors - ie a biodegradable polymer, in their drug eluting stent. Currently, at this price, the mkt cap of Biosensors is only abt US$500-600 million. |
| Useful To Me Not Useful To Me | |
|
|
|
|
winner80
Member |
17-Nov-2006 16:05
|
|
x 0
x 0 Alert Admin |
price is rising~ wat's the news? |
| Useful To Me Not Useful To Me | |
|
michaeltay
Member |
17-Nov-2006 10:13
|
|
x 0
x 0 Alert Admin |
Hi, its seems that they are stable but the price is slipping slowly any apparent reason for it? U guys think is still good to hold? |
| Useful To Me Not Useful To Me | |
|
maxsyn
Veteran |
14-Nov-2006 22:25
|
|
x 0
x 0 Alert Admin |
from CIMB research: Maintain Underperform and target price of S$0.76. Target price is based on probability-based DCF valuation (WACC:10%, flat terminal growth). We believe that risks (USFDA approval and commercialisation risk) continue to outweight potential opportunities offered by Biosensors at current valuations. Maintain Underperform. Target price is based on probability-based DCF valuation (WACC:10%, flat terminal growth). We believe that risks (USFDA approval and commercialisation risk) continue to outweight potential opportunities offered by Biosensors at current valuations. Maintain Underperform. |
| Useful To Me Not Useful To Me | |
|
|
|
|
maxsyn
Veteran |
11-Nov-2006 16:19
|
|
x 0
x 0 Alert Admin |
despite the loss, the counter managed to stay at current level, but lower than the recent high of 0.955. I think it has taken account into the latest result so should have limited down side. |
| Useful To Me Not Useful To Me | |
|
iPunter
Supreme |
10-Nov-2006 11:56
|
|
x 0
x 0 Alert Admin |
It is often said that when the good news comes out, the situation cannot, for the time being, be any better. So there won't be buyers, since buyers are driven by good news. Hence the price drops! :) Maybe it's as simple as that. Trade With Care ------------- |
| Useful To Me Not Useful To Me | |
|
hikitty
Master |
10-Nov-2006 11:42
|
|
x 0
x 0 Alert Admin |
LMA posted better third quarter results, yet the share has nosedived after the results were announced. Biosensors will experience the same fate. Beware - manipulators at work - by purposely selling down so as to be able to collect the shares at lower prices when other dump them. Shame to the "manipulators" of both LMA and Biosensors - both fundamentally sound yet have been lying low for some time. |
| Useful To Me Not Useful To Me | |
|
singaporegal
Supreme |
09-Nov-2006 21:23
Yells: "Female TA nut" |
|
x 1
x 0 Alert Admin |
Possibly on downtrend now. Bollinger bands really tight too... indicating a sudden price change downwards? Cautious... |
| Useful To Me Not Useful To Me | |
|
|
|
|
junjun
Member |
09-Nov-2006 19:18
|
|
x 0
x 0 Alert Admin |
NEWS RELEASE Biosensors Reports Increases in Product Revenue for Fiscal ?07 Second Quarter and First Half Singapore, 9 November 2006 - Biosensors International Group, Ltd. (?Biosensors? or
the ?Company?, Bloomberg: BIG SP) today reported its second fiscal quarter (?2Q
FY07?) and fiscal half year ended September 30, 2006 (?1H FY07?) financial results.
Total product revenue increased by 16 percent to US$8.2 million in 2Q FY07 from
US$7.0 million in the prior corresponding quarter, and increased by 25 percent to
US$16.1 million for the half year ending September 30, 2006 from US$12.9 million in the
prior fiscal half year. The increases are primarily due to growth in sales of its AxxionTM the ?Company?, Bloomberg: BIG SP) today reported its second fiscal quarter (?2Q FY07?) and fiscal half year ended September 30, 2006 (?1H FY07?) financial results. Total product revenue increased by 16 percent to US$8.2 million in 2Q FY07 from US$7.0 million in the prior corresponding quarter, and increased by 25 percent to US$16.1 million for the half year ending September 30, 2006 from US$12.9 million in the prior fiscal half year. The increases are primarily due to growth in sales of its AxxionTM TMdrug-eluting stent. Revenue from drug-eluting stents was US$3.0 million in the quarter compared with US$1.9 million in the prior year?s corresponding quarter, an increase of 58%. For the fiscal half year, revenue from drug-eluting stents increased by 161% to US$6.2 million compared to US$2.4 million in the prior fiscal half year. ?Biosensors? drug-eluting stent technology, particularly our biodegradable polymer technology, continued to be highlighted at this year?s Transcatheter Cardiovascular Therapeutics (?TCT?) symposium, held in Washington D.C. last week,? said Mr. Yoh- Chie Lu, Chairman and CEO of Biosensors. ?During the symposium, safety concerns associated with first generation drug-eluting stents with non-biodegradable polymer carriers continued to be an active topic of discussion among leading cardiologists. In the opinion of some cardiologists, the use of a biodegradable polymer may provide a viable alternative to treat coronary artery disease in the face of such safety concerns,? he added. ...... |
| Useful To Me Not Useful To Me | |